These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11182406)

  • 1. The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content.
    Bruckner BA; Stetson SJ; Farmer JA; Radovancevic B; Frazier OH; Noon GP; Entman ML; Torre-Amione G; Youker KA
    Am J Surg; 2000 Dec; 180(6):498-501; discussion 501-2. PubMed ID: 11182406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support.
    Bruckner BA; Stetson SJ; Perez-Verdia A; Youker KA; Radovancevic B; Connelly JH; Koerner MM; Entman ME; Frazier OH; Noon GP; Torre-Amione G
    J Heart Lung Transplant; 2001 Apr; 20(4):457-64. PubMed ID: 11295584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in myocardial collagen content before and after left ventricular assist device application in dilated cardiomyopathy.
    Liang H; Müller J; Weng YG; Wallukat G; Fu P; Lin HS; Bartel S; Knosalla C; Pregla R; Hetzer R
    Chin Med J (Engl); 2004 Mar; 117(3):401-7. PubMed ID: 15043781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness.
    Klotz S; Foronjy RF; Dickstein ML; Gu A; Garrelds IM; Danser AH; Oz MC; D'Armiento J; Burkhoff D
    Circulation; 2005 Jul; 112(3):364-74. PubMed ID: 15998679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support.
    Bruckner BA; Razeghi P; Stetson S; Thompson L; Lafuente J; Entman M; Loebe M; Noon G; Taegtmeyer H; Frazier OH; Youker K
    J Heart Lung Transplant; 2004 Jan; 23(1):36-42. PubMed ID: 14734125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery.
    Torre-Amione G; Stetson SJ; Youker KA; Durand JB; Radovancevic B; Delgado RM; Frazier OH; Entman ML; Noon GP
    Circulation; 1999 Sep; 100(11):1189-93. PubMed ID: 10484539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of improved right ventricular structure after LVAD support in patients with end-stage cardiomyopathy.
    Küçüker SA; Stetson SJ; Becker KA; Akgül A; Loebe M; Lafuente JA; Noon GP; Koerner MM; Entman ML; Torre-Amione G
    J Heart Lung Transplant; 2004 Jan; 23(1):28-35. PubMed ID: 14734124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): hemodynamic and histologic evidence of improvement before LVAD explantation.
    Khan T; Delgado RM; Radovancevic B; Torre-Amione G; Abrams J; Miller K; Myers T; Okerberg K; Stetson SJ; Gregoric I; Hernandez A; Frazier OH
    J Heart Lung Transplant; 2003 Feb; 22(2):137-46. PubMed ID: 12581761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group.
    Maybaum S; Mancini D; Xydas S; Starling RC; Aaronson K; Pagani FD; Miller LW; Margulies K; McRee S; Frazier OH; Torre-Amione G;
    Circulation; 2007 May; 115(19):2497-505. PubMed ID: 17485581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices.
    Li YY; Feng Y; McTiernan CF; Pei W; Moravec CS; Wang P; Rosenblum W; Kormos RL; Feldman AM
    Circulation; 2001 Sep; 104(10):1147-52. PubMed ID: 11535571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered myocardial phenotype after mechanical support in human beings with advanced cardiomyopathy.
    Altemose GT; Gritsus V; Jeevanandam V; Goldman B; Margulies KB
    J Heart Lung Transplant; 1997 Jul; 16(7):765-73. PubMed ID: 9257259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
    Klotz S; Danser AH; Foronjy RF; Oz MC; Wang J; Mancini D; D'Armiento J; Burkhoff D
    J Am Coll Cardiol; 2007 Mar; 49(11):1166-74. PubMed ID: 17367660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative changes in mast cell populations after left ventricular assist device implantation.
    Akgul A; Youker KA; Noon GP; Loebe M
    ASAIO J; 2005; 51(3):275-80. PubMed ID: 15968959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support.
    Grabellus F; Levkau B; Sokoll A; Welp H; Schmid C; Deng MC; Takeda A; Breithardt G; Baba HA
    Cardiovasc Res; 2002 Jan; 53(1):124-30. PubMed ID: 11744020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of prolonged left ventricular support on myocardial histopathology in patients with end-stage cardiomyopathy.
    Scheinin SA; Capek P; Radovancevic B; Duncan JM; McAllister HA; Frazier OH
    ASAIO J; 1992; 38(3):M271-4. PubMed ID: 1457863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of left ventricular assist device therapy on the cardiac proteome and metabolome composition in ischemic cardiomyopathy.
    Shahinian JH; Rog-Zielinska EA; Schlimpert M; Mayer B; Tholen S; Kammerer B; Biniossek ML; Beyersdorf F; Schilling O; Siepe M
    Artif Organs; 2020 Mar; 44(3):257-267. PubMed ID: 31494943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern.
    Bruggink AH; van Oosterhout MF; de Jonge N; Ivangh B; van Kuik J; Voorbij RH; Cleutjens JP; Gmelig-Meyling FH; de Weger RA
    J Heart Lung Transplant; 2006 Sep; 25(9):1091-8. PubMed ID: 16962471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial histological changes in dilated cardiomyopathy during a long-term left ventricular assist device support.
    Taketani S; Sawa Y; Fukushima N; Masai T; Kawaguchi N; Onishi S; Matsuda H
    Heart Vessels; 1997; 12(2):98-100. PubMed ID: 9403314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support.
    Lok SI; Nous FM; van Kuik J; van der Weide P; Winkens B; Kemperman H; Huisman A; Lahpor JR; de Weger RA; de Jonge N
    Eur J Cardiothorac Surg; 2015 Sep; 48(3):407-15. PubMed ID: 25609773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients.
    Thompson LO; Skrabal CA; Loebe M; Lafuente JA; Roberts RR; Akgul A; Jones V; Bruckner BA; Thohan V; Noon GP; Youker KA
    J Surg Res; 2005 Jan; 123(1):25-32. PubMed ID: 15652947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.